You are viewing: Italy Plasma Fractionation Market analysis
Part of: Plasma Fractionation Market (Global)

The Italy Plasma Fractionation Market was valued at $907 Million in 2026 and projected to reach to $1258.6 Million by 2031, representing a compound annual growth rate of 6.8%. Italy's plasma fractionation market is positioned for steady growth through 2031, supported by an aging population requiring specialized blood-derived therapies and a well-established healthcare infrastructure committed to advanced treatment options.

Italy Plasma Fractionation Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Italy Plasma Fractionation Market Trends and Insights

  • Italy's healthcare infrastructure and aging population drive demand for immunoglobulins, clotting factors, and albumin products essential for treating bleeding disorders, immunodeficiencies, and critical care applications.
  • The Italian market benefits from strong regulatory frameworks and established distribution networks that support plasma collection and fractionation operations across the country. Growth in Italy's plasma fractionation sector is underpinned by increasing prevalence of chronic diseases, rising surgical procedures, and heightened awareness of plasma-derived therapies among healthcare providers.
  • Italy's commitment to self-sufficiency in plasma supply and investments in modern fractionation facilities strengthen market expansion through 2031.
  • The country's participation in European Union blood and plasma regulations ensures quality standards while facilitating cross-border collaboration, positioning Italy as a key contributor to regional plasma fractionation capacity..

Key Market Statistics

  • CAGR (2026-2031) 6.8% CAGR
  • Market Size, 2026 ~USD 907 Million
  • Forecast, 2031 ~USD 1258.6 Million
  • Country Italy

Italy Plasma Fractionation Market Overview

Aging Population Driving Demand :

Italy's demographic shift toward an older population significantly increases demand for plasma-derived therapies, particularly immunoglobulins and clotting factors used in age-related conditions and immunodeficiencies.

Strong Healthcare Infrastructure :

Italy's advanced healthcare system and robust reimbursement policies support consistent adoption of plasma fractionation products across hospitals, clinics, and specialized treatment centers throughout the country.

Steady Market Expansion :

The Italian plasma fractionation market is projected to grow from USD 907.0 million in 2026 to USD 1,258.6 million by 2031, reflecting a stable CAGR of 6.8% driven by clinical demand and therapeutic innovation.

Critical Therapeutic Applications :

Albumin, immunoglobulins, and clotting factors remain essential treatments for bleeding disorders, primary immunodeficiencies, and critical care conditions, ensuring sustained market demand across Italian healthcare facilities.

Italy Plasma Fractionation Market Dynamics

  • The market's 6.8% CAGR reflects consistent clinical demand for immunoglobulins, clotting factors, and albumin products across Italian hospitals and specialized centers.
  • Regulatory support and reimbursement frameworks continue to facilitate product accessibility, while increasing awareness of rare bleeding and immunological disorders expands patient populations requiring plasma-derived treatments.
  • Italy's participation in European supply chains and manufacturing capabilities further strengthen market stability and product availability..

Market Ecosystem

logo-mobile

PLASMA FRACTIONATION MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Implemented the Horizon 2 plasma fractionation process at its Kankakee facility to improve immunoglobulin recovery from donated plasma Higher immunoglobulin yield | Improved plasma utilization | Greater production efficiency | Increased supply capacity
company logo
Implemented process improvements through its One Day Batch Release program at plasma-derived therapy manufacturing sites to accelerate batch release Faster batch release | Improved manufacturing efficiency | Shorter lead times | Faster product availability

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Pharmaceuticals

    Top Technologies
    • Bioreactors
    • Analytical Testing
    • Bioanalytical Testing Services
    • Cell Counters
    • Data Management Services
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • SANOFI
    • Pfizer Inc.
    • NOVARTIS

      Key Takeaways

      • Italy's plasma fractionation market is valued at USD 907.0 million in 2026 and will grow to USD 1,258.6 million by 2031 at a 6.8% CAGR.
      • Italy's aging demographic and rising chronic disease burden are primary drivers of demand for plasma-derived immunoglobulins and clotting factors.
      • Italy's EU regulatory alignment and focus on plasma self-sufficiency support sustainable market growth and operational investments.
      • Italy's established healthcare infrastructure and distribution networks position the country as a stable, growing market within the European plasma fractionation landscape.

      Plasma Fractionation Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment SCIG (Type)
      Forecast Period 2026-2030
      Growth Rate CAGR of 7.6% from 2026 to 2030
      Largest Segment THERAPEUTICS (Application)
      Market Size Base Year (Billions) ~USD 36.46 (2026)
      Revenue Forecast (Billions) ~USD 48.87 (2030)
      Segments Covered Product, Type, Application, Therapeutic Area, End User

      Italy Plasma Fractionation Market Report Segmentation

      5 segment dimensions are covered across the global market.

      By Product

      • Albumin
      • Coagulation Factor Concentrates
      • Immunoglobulins
      • Other Plasma Products
      • Protease Inhibitors

      By Type

      • Factor Ix
      • Factor Viii
      • Factor Xiii
      • Fibrinogen Concentrates
      • Ivig
      • Other Coagulation
      • Other Coagulation Factor Concentrates
      • Other Immunoglobulins
      • Prothrombin Complex Concentrates
      • Prothrombin Factor Concentrates
      • Scig
      • Von Willebrand Factor

      By Application

      • Academics & Preclinical Research
      • Therapeutics

      By Therapeutic Area

      • Critical Care
      • Hemato-Oncology
      • Hematology
      • Immunology
      • Neurology
      • Other Therapeutic Areas
      • Pulmonology
      • Rheumatology

      By End User

      • Home Care Settings & Infusion Centers
      • Hospitals & Specialty Clinics
      • Other End Users

      Target Audience

      • Pharmaceutical & Biotech Companies : Manufacturers and distributors of plasma-derived therapies need Italy-specific market data to guide product launches, market penetration strategies, and competitive positioning in this established European healthcare market.
      • Healthcare Investment Firms : Private equity and venture capital investors require detailed Italian market forecasts and growth metrics to evaluate investment opportunities in plasma fractionation companies and healthcare infrastructure assets.
      • Hospital & Clinical Networks : Italian healthcare providers and hospital procurement teams use market intelligence to optimize plasma product sourcing, budget allocation, and treatment protocol development for patient populations.
      • Regulatory & Policy Advisors : Government health agencies, regulatory consultants, and policy makers need Italy-specific market data to inform healthcare policy, reimbursement frameworks, and supply chain resilience strategies.
      • Market Research & Consulting Firms : Research organizations and management consultants require granular Italian market data to support client advisory services, competitive analysis, and strategic recommendations in the plasma fractionation sector.

      Reasons to Buy this Report

      • Precise Market Sizing for Italy : Access validated 2026-2031 market data specific to Italy's plasma fractionation sector, enabling accurate financial forecasting and investment decisions tailored to this mature European healthcare market.
      • Demographic Insights & Opportunity Assessment : Understand how Italy's aging population directly impacts demand for immunoglobulins, clotting factors, and albumin, identifying high-growth patient segments and therapeutic categories within the Italian market.
      • Competitive Landscape & Reimbursement Analysis : Gain intelligence on Italy's healthcare reimbursement policies, regulatory environment, and competitive dynamics to optimize market entry strategies and pricing models for plasma-derived products.
      • Growth Trajectory & Strategic Planning : Leverage the 6.8% CAGR forecast to benchmark performance, identify expansion opportunities, and develop long-term commercial strategies aligned with Italy's healthcare infrastructure and patient needs.
      • Regional Supply Chain Positioning : Evaluate Italy's role in European plasma fractionation supply chains and manufacturing capabilities to assess distribution opportunities and partnership potential within the Italian and broader EU markets.

      Frequently asked questions

      What is the current size of Italy's plasma fractionation market?

      Italy's plasma fractionation market is estimated at USD 907.0 million in 2026 and is expected to reach USD 1,258.6 million by 2031.

      What is the projected growth rate for Italy's plasma fractionation market?

      Italy's plasma fractionation market is projected to grow at a compound annual growth rate (CAGR) of 6.8% from 2026 to 2031.

      What factors are driving growth in Italy's plasma fractionation market?

      Key drivers include Italy's aging population, increasing prevalence of chronic diseases, rising surgical procedures, and heightened awareness of plasma-derived therapies among healthcare providers.

      How does Italy's regulatory environment support the plasma fractionation market?

      Italy's alignment with European Union blood and plasma regulations ensures quality standards, facilitates cross-border collaboration, and supports Italy's commitment to plasma self-sufficiency.

      What plasma-derived products are most in demand in Italy?

      Italy's market demand is strongest for immunoglobulins, clotting factors, and albumin products used to treat bleeding disorders, immunodeficiencies, and critical care conditions.

      RESEARCH METHODOLOGY

      This research study extensively used secondary sources, directories, and databases to identify and collect valuable information for analyzing the global plasma fractionation market. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market's growth prospects. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size..

      Secondary Research

      The secondary sources for this research study include publications from government sources, such as FDA/CBER, EMA, WHO, and national health and regulatory authorities; industry associations, such as the Plasma Protein Therapeutics Association (PPTA), the International Plasma and Fractionation Association (IPFA), and AABB; and commercial databases, such as Bloomberg Business, D&B, Factiva, and relevant trade databases. Additional sources include white papers, annual reports, company house documents, investor presentations, scientific and clinical publications, regulatory filings, patent databases, and product and clinical trial databases. Secondary research was used to identify and collect information for the extensive, technical, market-oriented, and commercial study of the plasma fractionation market. It was also used to obtain important information about key players, market classification, segmentation according to industry trends, the bottom-up approach, and key developments from market and technology perspectives. Secondary data was also used to assess plasma collection capacity, fractionation and manufacturing infrastructure, product portfolios, regulatory frameworks, trade patterns, clinical applications, and regional market trends. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market’s prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative information.

      Plasma Fractionation Market
 Size, and Share

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the plasma fractionation market. These methods were also used extensively to estimate the size of various market segments.

      Plasma Fractionation Market : Top-Down and Bottom-Up Approach

      Plasma Fractionation Market Top Down and Bottom Up Approach

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from both the demand and supply sides.

      Market Definition

      Plasma-derived therapies are medical treatments based on human plasma. Plasma is the largest component of human blood and contains water, salts, enzymes, antibodies, and other proteins. Before it can be used in medical therapies, it undergoes a fractionation process in which the relevant proteins are separated. Plasma-derived therapies are used to treat a wide range of (rare) diseases, from bleeding disorders and inhibitor deficiencies to primary and secondary immunodeficiencies.

      Key Stakeholders

      • Plasma Fractionation Product Manufacturers and Distributors
      • Pharmaceutical and Biotechnology Companies
      • Healthcare Service Providers (including Hospitals and Clinics)
      • Research and Development (R&D) companies
      • Academic Institutes
      • Government Associations
      • Market Research and Consulting Firms
      • Venture Capitalists and Investors

      Report Objectives

      • To define, describe, and forecast the plasma fractionation market based on product, application, therapeutic area, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall plasma fractionation market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the plasma fractionation market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the plasma fractionation market
      • To benchmark players within the plasma fractionation market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product/service strategy

      Available customizations:

      With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:

      Product Analysis

      • Further breakdown of the Rest of Europe Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Asia Pacific Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Latin America Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Middle East Plasma Fractionation Market, by country

      Company Information

      • Detailed analysis and profiling of additional market players (up to five)

      Get the Full Plasma Fractionation Market Report

      Full forecast, segment splits, and company analysis for all Plasma Fractionation Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status